Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

TScan Therapeutics

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Lilly’s Omvoh shows improved outcomes in ulcerative colitis

The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Abivax shares positive late-stage results for obefazimod in ulcerative colitis

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

- PMLiVE

Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links